Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.52 |
| ▸ | AHCY | P23526 | 8/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052485 | 0.81 | PRMT5 (0.38) | AHCYADORA2A | |
| SCHEMBL8140442 | 0.81 | PRMT5 (0.38) | AHCYADORA2A | |
| SCHEMBL12031062 | 0.81 | PRMT5 (0.38) | AHCYADORA2A | |
| SCHEMBL19993815 | 0.80 | ENPP1 (0.54) | — | |
| SCHEMBL19049955 | 0.79 | RET (0.38) | — | |
| SCHEMBL18831799 | 0.79 | HSP90AB1 (0.40) | — | |
| SCHEMBL23761010 | 0.77 | ADORA3 (0.43) | ADORA2AADORA1ADORA2B | |
| SCHEMBL19049972 | 0.77 | AHCY (0.33) | PI4KAPI4K2BPI4K2API4KBAHCY | |
| SCHEMBL12031349 | 0.76 | ADK (0.41) | — | |
| SCHEMBL19049958 | 0.76 | XDH (0.41) | PI4KAPI4K2BPI4K2API4KBAHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-9943539-B1 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200276222-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | PI4KA 3283/4885PI4K2B 1802/4885PI4K2A 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.